BioTime gets support from long-term investors

BioTime (BTX) secures $6.4M in equity financing from current shareholders. Proceeds will fund product development including the upcoming Renevia clinical trial as well as other operating expenses.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs